Clinical Trial Update: Merck IIT: RRP Pembro and Lenvatinib [EARLY_Phase 1]

View source ↗

Summary

A Yale-sponsored early-phase trial is evaluating pembrolizumab plus lenvatinib for recurrent respiratory papillomatosis caused by human papillomavirus; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Respiratory Papillomatosis

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Yale University | Conditions: Human Papilloma Virus, Recurrent Respiratory Papillomatosis | EARLY_Phase 1 | Status: RECRUITING